Germany · Delayed Price · Currency is EUR Marinomed Biotech AG Statistics
Total Valuation
FRA:93Z has a market cap or net worth of EUR 35.88 million. The enterprise value is 45.31 million.
| Market Cap | 35.88M |
| Enterprise Value | 45.31M |
Important Dates
The next estimated earnings date is Wednesday, April 22, 2026.
| Earnings Date | Apr 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.84M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.69% |
| Owned by Institutions (%) | 25.32% |
| Float | 1.31M |
Valuation Ratios
The trailing PE ratio is 3.94 and the forward PE ratio is 2.01.
| PE Ratio | 3.94 |
| Forward PE | 2.01 |
| PS Ratio | 3.68 |
| PB Ratio | -6.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.97 |
| EV / Sales | 4.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.74
| Current Ratio | 0.74 |
| Quick Ratio | 0.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.75% |
| Return on Invested Capital (ROIC) | -17.23% |
| Return on Capital Employed (ROCE) | -53.72% |
| Revenue Per Employee | 295,773 |
| Profits Per Employee | 276,270 |
| Employee Count | 47 |
| Asset Turnover | 1.03 |
| Inventory Turnover | 7.96 |
Taxes
| Income Tax | -117,980 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +67.58% |
| 50-Day Moving Average | 18.95 |
| 200-Day Moving Average | 16.75 |
| Relative Strength Index (RSI) | 43.16 |
| Average Volume (20 Days) | 1 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:93Z had revenue of EUR 9.76 million and earned 9.12 million in profits. Earnings per share was 5.13.
| Revenue | 9.76M |
| Gross Profit | 6.47M |
| Operating Income | -1.93M |
| Pretax Income | 9.00M |
| Net Income | 9.12M |
| EBITDA | -1.57M |
| EBIT | -1.93M |
| Earnings Per Share (EPS) | 5.13 |
Balance Sheet
The company has 1.49 million in cash and 10.92 million in debt, giving a net cash position of -9.43 million.
| Cash & Cash Equivalents | 1.49M |
| Total Debt | 10.92M |
| Net Cash | -9.43M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -5.44M |
| Book Value Per Share | -3.06 |
| Working Capital | -1.06M |
Cash Flow
| Operating Cash Flow | -800,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 66.33%, with operating and profit margins of -19.81% and 93.41%.
| Gross Margin | 66.33% |
| Operating Margin | -19.81% |
| Pretax Margin | 92.20% |
| Profit Margin | 93.41% |
| EBITDA Margin | -16.09% |
| EBIT Margin | -19.81% |
| FCF Margin | n/a |
Dividends & Yields
FRA:93Z does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.17% |
| Shareholder Yield | -17.17% |
| Earnings Yield | 25.41% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:93Z has an Altman Z-Score of -7.97 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.97 |
| Piotroski F-Score | 4 |